Patients with high-risk prostate cancer treated with curative intent are at an increased risk of
biochemical recurrence, metastatic progression and cancer-related death compared with …

Background Hormone therapy for early prostate cancer has demonstrated an improvement
in clinical and pathological variables, but not always an improvement in overall survival. We …

BACKGROUND: We performed a systematic review and meta-analysis of randomised trials
of neo-adjuvant hormone therapy (NHT) in localised and locally advanced prostate cancer …

The majority of patients with prostate cancer who later develop lethal metastatic disease
have high-risk localized disease at presentation, emphasizing the importance of effective …

Prostate cancer development and progression is the result of complex interactions between
epithelia cells and fibroblasts/myofibroblasts, in a series of dynamic process amenable to …

Background Patients with high-risk prostate cancer have an increased likelihood of
experiencing a relapse following radical prostatectomy (RP). We previously conducted three …

BACKGROUND: Preoperative treatment of prostate cancer (PCa) changes morphology of
residual tumors so that the Gleason score is no longer valid. OBJECTIVE: To codify …

High-risk localized prostate cancer remains a lethal disease with high rates of recurrence,
metastases and death, despite attempts at curative local treatment including surgery …

Androgens play a prominent role in the development, maintenance and progression of
prostate cancer. The introduction of androgen deprivation therapies into the treatment …

This study aimed to identify the pathological outcomes and survival benefits of neoadjuvant
hormone therapy (NHT) combined with radical prostatectomy (RP) and radiotherapy (RT) …